Mar 24, 2025

SNBL’s Subsidiary, SNLD, Announces its Abstract Accepted at the Upcoming 77th American Academy of Neurology (AAN) 2025 Annual Meeting

Nov 26, 2024

SNBL’s Subsidiary, Satsuma Pharmaceuticals Receives FDA Acceptance of NDA Resubmission of STS101 for the Acute Treatment of Migraine With or Without Aura

Oct 31, 2024

SNBL’s Subsidiary Satsuma Pharmaceuticals Resubmits New Drug Application for STS101 for Acute Treatment of Migraine With or Without Aura

Jan 18, 2024

FDA Issues Complete Response Letter for Satsuma’s STS101 

June 26, 2023

SNBL Announces Results of Collaboration Research with Hamamatsu University School of Medicine  Using SNBL’s Nose-to-Brain Delivery Technology

May 19, 2023

Satsuma Pharmaceuticals Announces FDA Acceptance of NDA for STS101, a Novel and Investigational DHE Nasal Powder Product for the Acute Treatment of Migraine

April 17, 2023

SNBL Enters into Definitive Agreement to Acquire Satsuma Pharmaceuticals, Inc.

November 24, 2022

SNBL’s Comments on Results from Clinical Phase 3 Studies of STS101, an Investigational Migraine Drug Candidate, Announced by Satsuma Pharmaceuticals, Inc.

November 14, 2022

Satsuma Pharmaceuticals Announces Topline Results from the STS101 SUMMIT Phase 3 Efficacy Trial for the Acute Treatment of Migraine

September 21, 2022

Satsuma Pharmaceuticals Announces Positive Results from the Ongoing STS101 ASCEND Phase 3 Open-label, Long-term Safety Trial

August 02, 2021

Satsuma Pharmaceuticals Announces First Subject Randomized in the Phase 3 SUMMIT Efficacy Trial of STS101 for Acute Treatment of Migraine

June 17, 2021

Satsuma Pharmaceuticals, Inc. Announces Positive PK, Tolerability, and Safety Results From Phase 1 Trial of STS101 at Multiple Dose Strengths

March 02, 2021

Satsuma Pharmaceuticals, Inc. Announces Updated STS101 Development Plan

September 11, 2020

Satsuma Pharmaceuticals, Inc. Announces Topline Results from EMERGE Phase 3 Trial of STS101 for the Acute Treatment of Migraine

August 07, 2020

Satsuma Pharmaceuticals Announces Enrollment of First Patient in the  ASCEND Phase 3 Open-label Trial of STS101 for  Acute Treatment of Migraine

June 01, 2020

Satsuma Pharmaceuticals, Inc. Announces Completion of Enrollment for Phase 3 EMERGE Trial of STS101 for Acute Treatment of Migraine

May 19, 2020

Satsuma Pharmaceuticals, Inc. Announces Poster Presentations on the American Academy of Neurology 2020 Science Highlights Virtual Platform

May 12, 2020

Satsuma Pharmaceuticals, Inc. Reports STS101 Development Progress in its First Quarter 2020 Financial Results

February 03, 2020

Satsuma Pharmaceuticals, Inc. Announces Publication of STS101 Phase 1 Clinical Trial Results in Headache: The Journal of Head and Face Pain

September 17, 2019

Satsuma Pharmaceuticals, Inc. Listed on NASDAQ

August 23, 2019

Satsuma Pharmaceuticals, Inc. Announces First Patient Dosed in EMERGE, a Phase 3 Efficacy Trial of STS101 for the Acute Treatment of Migraine